Biosimilar portfolio & partnerships

Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of multiple biosimilar candidates.

We have developed an extensive and ever-growing pipeline of biosimilars to treat a number of conditions across major therapeutic areas. Many of these biosimilars have already been partnered, the most advanced of which are listed below.

We consistently invest in the start of one biosimilar development per year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment.

The ultimate goal of our biosimilar development is to partner with companies who have the reach to maximize the access to patients who need such high quality medicines.

Our biosimilar pipeline

INN
Originator
Therapeutic area
Partner
Cell line development
Process and formulation development
Clinical development
Submission
Ranibizumab FYB201
Lucentis
Ophthalmology
BioEq
Natalizumab PB006
Tysabri
Multiple sclerosis
Sandoz
Vedolizumab PB016
Entyvio
Immunology
-
Ipilimumab PB008
Yervoy
Oncology
-
Ocrelizumab PB018
Ocrevus
Multiple sclerosis
-
Pembrolizumab PB014
Keytruda
Oncology
-
Nivolumab PB015
Opdivo
Oncology
-
INN Ranibizumab FYB201
Originator Lucentis
Therapeutic area Ophthalmology
Partner BioEq
Cell line development
Process and formulation development
Clinical development
Submission
INN Natalizumab PB006
Originator Tysabri
Therapeutic area Multiple sclerosis
Partner Sandoz
Cell line development
Process and formulation development
Clinical development
Submission
INN Vedolizumab PB016
Originator Entyvio
Therapeutic area Immunology
Partner -
Cell line development
Process and formulation development
Clinical development
Submission
INN Ipilimumab PB008
Originator Yervoy
Therapeutic area Oncology
Partner -
Cell line development
Process and formulation development
Clinical development
Submission
INN Ocrelizumab PB018
Originator Ocrevus
Therapeutic area Multiple sclerosis
Partner -
Cell line development
Process and formulation development
Clinical development
Submission
INN Pembrolizumab PB014
Originator Keytruda
Therapeutic area Oncology
Partner -
Cell line development
Process and formulation development
Clinical development
Submission
INN Nivolumab PB015
Originator Opdivo
Therapeutic area Oncology
Partner -
Cell line development
Process and formulation development
Clinical development
Submission
  • Natalizumab PB006
  • Vedolizumab PB016
  • Ranibizumab FYB201

Brand name:

Tysabri®

Partner:

Sandoz

Originator:

Natalizumab

Annual sales:

$1.9bn (2019)

Therapeutic area:

Multiple sclerosis

Natalizumab, sold under the brand name Tysabri® among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage. Natalizumab was approved by the FDA 2004.

Natalizumab biosimilar PB006

Polpharma Biologics is developing a Natalizumab biosimilar code named PB006. Our partner, Sandoz will commercialize this medicine. Global phase III & phase I PK/PD clinical trials of PB006 both completed recruitment in 2020.

Brand name:

Entyvio®

Partner:

Available

Originator:

Vedolizumab

Annual sales:

$3.2bn (2019)

Therapeutic area:

Immunology

Vedolizumab, sold under the brand name Entyvio® is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc (a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7. Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.

Vedolizumab biosimilar PB016

Polpharma Biologics is developing a Vedolizumab biosimilar PB016. Following technical proof of similarity and scale up, GMP production will start in 2021.

Brand name:

Lucentis®

Partner:

Bioeq AG

Originator:

Ranibizumab

Annual sales:

$4bn (2019)

Therapeutic area:

Ophthalmology

In addition to the molecules listed above, Polpharma Biologics, through a JV (Bioeq), and in collaboration with Formycon, is working on a Ranibizumab biosimilar, code named FYB201. FYB201 will be commercialized in the US by Coherus.

Ranibizumab biosimilar FYB201

Ranibizumab (trade name Lucentis® among others) is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration a common form of age-related vision loss. In 2019, Lucentis® generated global sales of more than USD 3.9 billion, with revenue growth continuing at a significant rate.

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.